Abstract: The present invention relates to pharmaceutical compositions comprising safinamide and, more particularly, to taste-masked particles comprising said active ingredient or pharmaceutically acceptable salts thereof, oral dosage forms that include said particles and a process for preparing them.

Abstract: The present invention relates to a method for the production of a biopolymer, wherein the biopolymer has a defined average molecular weight, the method comprising lyophylizing a composition comprising the biopolymer with native high molecular weight, optionally purifying and/or isolating the biopolymer; wherein the temperature during the sublimation process is selected to facilitate a controlled and defined degradation of said biopolymer.

Abstract: Techniques regarding polymers with antimicrobial functionality are provided. For example, one or more embodiments described herein can regard a polymer, which can comprise a repeating ionene unit. The repeating ionene unit can comprise a cation distributed along a degradable backbone. The degradable backbone can comprise a terephthalamide structure. Further, the repeating ionene unit can have antimicrobial functionality.

Abstract: A method of preserving the one or more chemical and/or biological species in a polymer matrix comprising pullulan and trehalose is described. The method includes combining the one or more chemical and/or biological species, an aqueous pullulan and a trehalose solution and drying the resultant mixture to provide a solid polymeric matrix. A polymeric matrix comprising one or more chemical and/or biological species and its use, for example, on surfaces for food preparation, for food preservation and in biological preparations is also described.

Abstract: Provided is tunable biopolymer hydrogel produced from two processed natural polysaccharides for use as a hemostat. If desired, the hydrogel formation can be tuned so that the hydrogel forms within seconds when applied to a tissue lesion. The resulting hydrogel can adhere to tissue and, without swelling, produce hemostasis within seconds after application to tissue of interest. The hydrogel also captures, aggregates and concentrates platelets and red blood cells at the site of the tissue lesion thereby initiating a clotting cascade at the site of the lesion. The hemostat can be used to prevent blood loss during surgical procedures, for example, during brain, spine or other surgical procedures where hemostasis is desirable, and is particularly useful during surgical procedures where swelling of the hemostat (e.g., in the brain or spine) would be detrimental to the subject.

Abstract: The instant disclosure relates to a composition for topical application to the skin comprising a first pearlescent uncoated pigment having an average particle size of 25 um or less; a second pearlescent pigment having an average particle size of 25 um or less, completely or partially coated with one or more layers of metal oxides; a first mica having an average size of 42 um or less, completely or partially coated with one or more layers of red iron oxide; and a second mica having an average size of 25 um or less, completely or partially coated with one or more layers of titanium dioxide. It also relates to methods of using said compositions.

Abstract: There is provided a polymer comprising: (i) a repeat unit derived from a compound of formula (I) (Formula (I)) wherein, R1 and R2 are each independently selected from OH, OR?, SH, SR?, NH2, NHR? and NR?2; R? is C1-20 hydrocarbyl; each n is independently 0 or an integer between 1 and 6; each m is independently 0 or an integer between 1 and 4, and preferably at least one m is 1; and q is an integer between 1 and 8; and; (ii) a biologically active molecule, wherein said biologically active molecule is covalently bonded to said repeat unit; as well as methods for preparing such polymers, particles comprising said polymers and uses of said polymers and particles including use in the treatment of disease.

Abstract: A biocide resin composition that includes one or more solutions of selected melamine-formaldehyde, urea-formaldehyde, phenol-formaldehyde, melamine-urea-formaldehyde, and phenolic resins, and more than one copper salt soluble in aqueous systems and melamine-formaldehyde, urea-formaldehyde, and phenolic solutions. Copper salts are of the copper citrate, copper lysinate, copper gluconate, copper salicylate, copper phthalocyanine, copper chelate, copper oxalate, copper acetate, copper methionine, copper tartrate, copper glycinate, copper picolinate, copper aspartate, ammoniacal copper complexes, EDTA (ethylenediaminetetraacetic acid)-copper complexes, copper glycolate, copper glycerate, copper ascorbate type and, in general, copper salts of the organic type, R—Cu, R1-Cu—R2, where R, R1, and R2 can be alkyl chains (C3-C18) with one or more acid, aldehyde, ester, ether, hydroxyls, amino, or others groups in its structure.

Abstract: A method for treating a prokaryotic infection in an animal or human by administering a pharmaceutically acceptable composition, comprising administering a source of silver ions and a benzoisoselenazol derivative, e.g., an ebselen derivative.

Abstract: Techniques regarding chemical compounds with antimicrobial functionality are provided. For example, one or more embodiments describe herein can comprise a monomer that can comprise a molecular backbone. The molecular backbone can comprise a bis(urea)guanidinium structure covalently bonded to a functional group, which can comprise a radical. Also, the monomer can have supramolecular assembly functionality.

Abstract: Nanoscale, pH-responsive polycationic networks useful for the delivery of anionic biologic therapeutics and associated methods.

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

Abstract: The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase is dispersed in the aqueous surfactant matrix. The present application also relates to methods of delivering the active agent(s) to a subject in need thereof topically, for example to the skin, the hair, and scalp. The present application also relates to use of the rinse-off compositions to treat and/or prevent topical conditions such as dermatitis and psoriasis. In some embodiments, the rinse-off compositions of the present application are shampoo compositions.

Abstract: A non-covalent complex of an albumin molecule and a hydrophobic ligand, compositions containing the same, and methods of use thereof are provided. The present complex may find use in delivering the hydrophobic ligand to microorganisms that have albumin-binding outer surfaces, such as a cell wall.

Abstract: A method of manufacturing a series of capsules (1A) comprising a core (3), and a gelled envelope (5) completely encapsulating the core and comprising at least two external phases (5A, 5B), wherein the gelled envelope has a external surface comprising at least two distinct portions (7A, 7B) formed respectively by the two external phases, and comprising the following steps: conveying a first flow (F1) that is intended to form the core, and a second flow (F2) of at least the two external phases that are intended to form the gelled envelope, wherein each external phase contains a liquid polyelectrolyte that is able to gel, at least one of the two external phases comprising a coloring agent, while the second flow surrounds the first flux about an axis (D2); successive formation of a plurality of liquid bodies (57) comprising a drop (107), and a film coating (109) coating the drop and having the two external phases, wherein the film has on its external surface at least two portions (109A, 109B) formed by the two

Abstract: Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.

Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for coating of any material where reduced fibrosis is desired, such as encapsulated cells for transplantation and medical devices implanted or used in the body.

Abstract: A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.

Abstract: The invention is directed to a nerve cap for covering a nerve stump, comprising a tubular body with a closed end and an open end and essentially consisting of biodegradable polymeric material to prevent or treat symptoms caused by neuroma. The polymeric material preferably comprises a poly(DL-lactide-co-?-caprolactone) copolymer obtained by the copolymerizaton of DL-lactide and ?-caprolactone, which copolymer has a lactide content of 51-75 mol %.

Abstract: A condom assembly includes at least one of a condom, patch or glove made of at least one of natural latex, synthetic latex or the mixture of natural latex and synthetic latex. The natural latex, synthetic latex or the mixture of natural latex and synthetic latex contain prodrugs of nitric oxide and/or other active ingredients.